Why is Eli Lilly and Company (LLY) stock trending?
- Eli Lilly's weight loss drug, Tirzepatide, has shown similar side effects to rival drug VK2735, with VK2735 able to match Tirzepatide's weight loss in as little as 33 weeks.
- Aarti Shah, former senior VP at Eli Lilly, has been appointed to the board of NVDA, a semiconductor company.
- Eli Lilly's weight loss drug, TZP, may lose market share to VKTX's Vanquish 2, which has shown more effective weight loss and better A1C results in clinical trials.
| Attention | 30-day average attention | Change | |
|---|---|---|---|
| LLY | |||
| LLY | 0.4% | 0.14% | +0.26 pts |
Is LLY stock sentiment bullish or bearish?
| Bullish | Bearish | ||
|---|---|---|---|
| LLY | |||
| LLY | 60% | 40% | |
| LLY, 30-day average | |||
| LLY, 30-day average | 84% | 16% | |
| Healthcare sector | |||
| Healthcare sector | 62% | 38% | |
| All stocks | |||
What are investors saying about LLY stock?
We train models to sort every post about Eli Lilly and Company into topics, then summarize what each group is saying. Each bar is the share of the engagement on LLY posts that went to that topic.
| Share of engagement | 30-day average share | ||
|---|---|---|---|
| Announcements company announcements | |||
| Announcements company announcements | 92% | 5% | |
What has LLY announced?
- Eli Lilly is expanding its weight-care program to allow US employers to cover the cost of FDA-approved GLP-1 medications from Novo Nordisk and Eli Lilly, starting January 2027.
- Eli Lilly is acquiring Calytrix Bio for up to $1.5 billion to add an experimental antibody for rare blood cancers, with the deal including a cash payment and potential milestones.
What is the latest news on LLY stock?
- Rhythm Pharma: Is AstraZeneca/Eli Lilly's Bidding War For Real? Don't Rule It Out
Rhythm Pharma's Imcivree generated $92.1 million in Q3; its estimated $8.25 billion market cap exceeds 20 times estimated 2026 revenue. I rate RYTM stock as Hold.
Seeking Alpha · 8h ago - Health Canada approves Lilly's Mounjaro® (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetesYahoo Finance · 10h ago
- Breakingviews - COMMENTARY: Eli Lilly’s $1.4 trln valuation is heavy with hopeReuters · 23h ago
- Rythm Pharmaceuticals gains on report Eli Lilly made $150/share offer with CVR
Rhythm Pharmaceuticals rose 3.6% as traders cited an alert that Eli Lilly submitted a rival bid near $150 per share plus a contingent value right.
Seeking Alpha · 1d ago - Eli Lilly Inks Multibillion-Dollar Pact to Develop Precision Cancer TherapiesBenzinga · 1d ago
Who is talking about LLY stock?
| Newcomers | Regulars | ||
|---|---|---|---|
| LLY | |||
| LLY | 97% | 3% | |
| LLY, 30-day average | |||
| LLY, 30-day average | 35% | 65% | |
| All stocks | |||
| All stocks | 43% | 57% | |
How does LLY compare with other Healthcare stocks?
We compare Healthcare stocks by attention, our measure of how much of the conversation each one gets. We add up the likes, replies and reposts on every post about Healthcare stocks on X, Reddit, Stocktwits and YouTube. A stock's attention is its share of that total. Each bar is that share.
| Share of Healthcare attention | ||
|---|---|---|
| LLY | ||
| LLY | 3.9% | |
| SLS | ||
| SLS | 29% | |
| CAPR | ||
| CAPR | 8.1% | |